Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Tracon Pharma (TCON)

8.22   0.07 (0.86%) 03-07 04:43
Open: 8.2 Pre. Close: 8.15
High: 8.49 Low: 6.81
Volume: 654,360 Market Cap: 127M
TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead clinical stage products include envafolimab (KN035), an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma. The company's clinical stage products also include DE-122, which is in randomized Phase IIa study for the treatment of wet AMD; TRC102, which is a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, Phase I clinical trial to treat solid tumors, Phase I/II to treat solid tumors and lymphomas, and Phase I trial to treat lung cancer; TRC253, a small molecule, which is in a Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Janssen Pharmaceutica N.V. for the development of TRC253; Santen Pharmaceutical Co. Ltd. for the development of carotuximab products for ophthalmology indications; Roswell Park Cancer Institute and Health Research Inc.; Case Western Reserve University; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 8.51 - 8.566 8.566 - 8.617
Low: 6.695 - 6.754 6.754 - 6.808
Close: 8.111 - 8.222 8.222 - 8.322

Technical analysis

as of: 2021-03-05 5:13:49 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 11.53     One year: 13.74
Support: Support1: 6.81    Support2: 5.67
Resistance: Resistance1: 9.87    Resistance2: 11.76
Pivot: 9.63
Moving Average: MA(5): 8.57     MA(20): 9.86
MA(100): 8.42     MA(250): 4.77
MACD: MACD(12,26): -0.44     Signal(9): -0.19
Stochastic oscillator: %K(14,3): 18.09     %D(3): 19.27
RSI: RSI(14): 37.58
52-week: High: 12.20  Low: 0.95  Change(%): 273.6
Average Vol(K): 3-Month: 61533  10-Days: 57039

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
TCON has closed above bottom band by 15.6%. Bollinger Bands are 50.4% wider than normal. The large width of the bands suggest high volatility as compared to TCON's normal range. The bands have been in this wide range for 1 bars. This is a sign that the current trend might continue.

Headline News

Sun, 28 Feb 2021
Taking A Gander At Tracon Pharmaceuticals - Seeking Alpha

Fri, 26 Feb 2021
TRACON Pharmaceuticals ends FY2020 with $36.1M in cash and equivalents - Proactive Investors USA & Canada

Fri, 26 Feb 2021
Should Biotechnology Stock TRACON Pharmaceuticals Inc (TCON) Be in Your Portfolio Friday? - InvestorsObserver

Thu, 25 Feb 2021
Tracon: 4Q Earnings Snapshot - San Francisco Chronicle

Thu, 25 Feb 2021
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update - GlobeNewswire

Thu, 25 Feb 2021
TRACON Pharmaceuticals - Consensus Indicates Potential 29.1% Upside - DirectorsTalk Interviews

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 15
Shares Float (M) 8
% Held by Insiders 2.02
% Held by Institutions 38.55
Shares Short (K) 333
Shares Short P. Month (K) 179

Stock Financials

EPS -2.600
EPS Est This Year -1.570
EPS Est Next Year -1.830
Book Value (p.s.) 1.130
Profit Margin
Operating Margin
Return on Assets (ttm) -40.2
Return on Equity (ttm) -168.0
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -1.090
Qtrly Earnings Growth
Operating Cash Flow (M) -18
Levered Free Cash Flow (M) -11

Stock Valuations

PE Ratio -3.16
PEG Ratio
Price to Book value 7.27
Price to Sales
Price to Cash Flow -6.76

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.